Contraception (Birth Control) and Family Planning PubHealthInfo

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]

Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

YEAR: 1998

CATEGORY: Contraception (Birth Control) and Family Planning

TITLE

Oral contraceptives and the risk of hereditary ovarian cancer.

AUTHORS

Narod SA; Risch H; Moslehi R; Dorum A; Neuhausen S; Olsson H; Provencher

D; Radice P; Evans G; Bishop S

SOURCE

NEW ENGLAND JOURNAL OF MEDICINE. 1998 Aug 13;339(7):424-8.

ABSTRACT

Approximately 10% of invasive epithelial ovarian cancers are hereditary, occurring predominantly in women with

mutations in either the BRCA1 or BRCA2 gene. Although oral contraceptives (OCs) protect against ovarian cancer, it

is not known whether this protective effect applies to hereditary forms of the disease. The present case-control

study compared lifetime histories of OC use in 207 North American and European ovarian cancer patients with

BRCA1 or BRCA2 mutations who were born in 1925-60 and the 161 living sisters of these women. 50% of cases and

70% of controls reported a history of OC use; the average durations of use were 4 years and 6 years, respectively.

After adjustment for year of birth and parity, the odds ratio (OR) associated with any past OC use was 0.5 (95%

confidence interval (CI), 0.3-0.8). This risk decreased significantly with increasing duration of use; OC use for 6

years or more was associated with a 60% risk reduction. The protective effect of OCs was noted in carriers of both

the BRCA1 mutation (OR, 0.5; 95% CI, 0.3-0.9) and the BRCA2 mutation (OR, 0.4; 95% CI, 0.2-1.1). These results

suggest that OC administration should be considered for prevention of ovarian cancer among women with BRCA1 or

BRCA2 mutations. However, the specific formulations to recommend and the age at which OC treatment should

begin remain to be determined. (PubHealth.info Document ID: CONT2T 5-06)

PubHealth.info NOTE: The author(s) of this article titled, "Oral contraceptives and the risk of hereditary ovarian

cancer.", is(are) Narod SA; Risch H; Moslehi R; Dorum A; Neuhausen S; Olsson H; Provencher D; Radice P;

Evans G; Bishop S. The source of this article is "NEW ENGLAND JOURNAL OF MEDICINE. 1998 Aug

13;339(7):424-8.". This article was published in 1998 in English language(s). (PubHealth.info® Document ID:

CONT2T 5-06. All rights reserved with PubHealth.info) PIN: 5005

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.